» Articles » PMID: 18835883

Substance P (SP) Enhances CCL5-induced Chemotaxis and Intracellular Signaling in Human Monocytes, Which Express the Truncated Neurokinin-1 Receptor (NK1R)

Overview
Journal J Leukoc Biol
Date 2008 Oct 7
PMID 18835883
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Substance P (SP) is a potent modulator of monocyte/macrophage function. The SP-preferring receptor neurokinin-1 receptor (NK1R) has two forms: a full-length NK1R (NK1R-F) isoform and a truncated NK1R (NK1R-T) isoform, which lacks the terminal cytoplasmic 96-aa residues. The distribution of these receptor isoforms in human monocytes is not known. We previously identified an interaction among SP, NK1R, and HIV viral strains that use the chemokine receptor CCR5 as a coreceptor, suggesting crosstalk between NK1R and CCR5. The purpose of this study was to determine which form(s) of NK1R are expressed in human peripheral blood monocytes and to determine whether SP affects proinflammatory cellular responses mediated through the CCR5 receptor. Human peripheral blood monocytes were found to express NK1R-T but not NK1R-F. SP interactions with NK1R-T did not mobilize calcium (Ca2+), but SP mobilized Ca2+ when the NK1R-F was transfected into monocytes. However, the NK1R-T was functional in monocytes, as SP enhanced the CCR5 ligand CCL5-elicited Ca2+ mobilization, a response inhibited by the NK1R antagonist aprepitant. SP interactions with the NK1R-T also enhanced CCL5-mediated chemotaxis, which was ERK1/2-dependent. NK1R-T selectively activated ERK2 but increased ERK1 and ERK2 activation by CCL5. Activation of NK1R-T elicited serine phosphorylation of CCR5, indicating that crosstalk between CCL5 and SP may occur at the level of the receptor. Thus, NK1R-T is functional in human monocytes and activates select signaling pathways, and the NK1R-T-mediated enhancement of CCL5 responses does not require the NK1R terminal cytoplasmic domain.

Citing Articles

Role of neurogenic inflammation in intervertebral disc degeneration.

Peng B, Li Y, Yang L World J Orthop. 2025; 16(1):102120.

PMID: 39850033 PMC: 11752484. DOI: 10.5312/wjo.v16.i1.102120.


From pain to tumor immunity: influence of peripheral sensory neurons in cancer.

Mardelle U, Bretaud N, Daher C, Feuillet V Front Immunol. 2024; 15:1335387.

PMID: 38433844 PMC: 10905387. DOI: 10.3389/fimmu.2024.1335387.


Post COVID-19 complications and follow up biomarkers.

Abdullah M, Ali A, Usman M, Naz A, Qureshi J, Bajaber M Nanoscale Adv. 2023; 5(21):5705-5716.

PMID: 37881715 PMC: 10597564. DOI: 10.1039/d3na00342f.


Tachykinins and the potential causal factors for post-COVID-19 condition.

Janket S, Fraser D, Baird A, Tamimi F, Sohaei D, Conte H Lancet Microbe. 2023; 4(8):e642-e650.

PMID: 37327802 PMC: 10263974. DOI: 10.1016/S2666-5247(23)00111-8.


Neuro-immune interactions and immuno-oncology.

Khanmammadova N, Islam S, Sharma P, Amit M Trends Cancer. 2023; 9(8):636-649.

PMID: 37258398 PMC: 10524972. DOI: 10.1016/j.trecan.2023.05.002.


References
1.
Lee H, Ho W, Douglas S . Substance P augments tumor necrosis factor release in human monocyte-derived macrophages. Clin Diagn Lab Immunol. 1994; 1(4):419-23. PMC: 368279. DOI: 10.1128/cdli.1.4.419-423.1994. View

2.
Lai J, Yang J, Douglas S, Wang X, Riedel E, Ho W . Quantification of CCR5 mRNA in human lymphocytes and macrophages by real-time reverse transcriptase PCR assay. Clin Diagn Lab Immunol. 2003; 10(6):1123-8. PMC: 262429. DOI: 10.1128/cdli.10.6.1123-1128.2003. View

3.
OConnor T, OConnell J, OBrien D, Goode T, Bredin C, Shanahan F . The role of substance P in inflammatory disease. J Cell Physiol. 2004; 201(2):167-80. DOI: 10.1002/jcp.20061. View

4.
Koon H, Zhao D, Na X, Moyer M, Pothoulakis C . Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem. 2004; 279(44):45519-27. DOI: 10.1074/jbc.M408523200. View

5.
Li B, Wetzel M, Mikovits J, Henderson E, Rogers T, Gong W . The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of formyl peptide receptor-like 1. Blood. 2001; 97(10):2941-7. DOI: 10.1182/blood.v97.10.2941. View